StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $5.41 | $5.09 | -5.91% | 0.8M |
| 05-18 | $5.11 | $4.71 | -7.83% | 0.9M |
| 05-19 | $4.66 | $4.48 | -3.86% | 1.0M |
| 05-20 | $4.48 | $5.12 | +14.29% | 1.8M |
| 05-21 | $5.00 | $5.23 | +4.60% | 0.3M |
No sell-side coverage available for LXEO yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2022 2022-12-31 | Q3 2022 2022-09-30 |
|---|---|---|
Revenue | $654.00K | $654.00K |
Operating Income | $-60.51M | $-45.31M |
Net Income | $-59.28M | $-44.70M |
EPS (Diluted) | $-36.36 | $-27.50 |
Total Assets | $97.08M | Not available |
Total Liabilities | $25.00M | Not available |
Cash & Equivalents | $77.33M | $94.15M |
Free Cash Flow OCF − CapEx | $-55.23M | $-38.58M |
Shares Outstanding | 1.61M | 1.63M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.